Back to top
more

Amplify Treatments, Testing and Advancements ETF: (GERM)

(Delayed Data from NYSE) As of Apr 17, 2024 10:09 AM ET

$16.63 USD

16.63
407

-0.13 (-0.77%)

Volume: 407

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

ETF Quote Details

Previous Close 16.76
Open 16.63
Bid 8.30
Ask 18.50
Day Low-High 16.63-16.63
52wk Low-High 15.67-21.70
Volume 407
NAV (month end) 18.50
Premium (+)/Discount (-) (month end)-1.74

Zacks Premium Research for GERM

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 NA
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

NA
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.68%
Dividend (Yield) $0.21 (1.24%)
Issuer AMPLIFY ETFS

Benchmark for GERM

PRIME TREATMENTS TESTING & ADVNCMNTS ID

The Prime Treatments, Testing and Advancements Index provides investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

Fund Summary for GERM

AMPLIFY TREATMENTS TESTNG & ADVNCMNT ETF

The Amplify Treatments, Testing and Advancements ETF seeks investment results that generally correlate, before fees and expenses, to the total return performance of the Prime Treatments, Testing and Advancements Index.